Cancer Network
Spotlight
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer UpdatesCancerNetwork® Inaugural Face-OffContemporary Concepts in Hematologic OncologyInsights from Experts at Mayo Clinic on Translating Evidence to Clinical PracticeOptimizing Outcomes in Patients with HER2+ Metastatic Breast CancerReal-World Evidence in NSCLC Guides Clinical Decisions Register: Developments in GVHD Prevention and TreatmentTargeting NSCLC with Uncommon EGFR Mutations
Clinical
View MoreAcute Myeloid LeukemiaBrain CancerBreast CancerColorectal CancerGastrointestinal CancerGenitourinary CancerGynecologic CancerHematologyLeukemiaLung CancerLymphomaPediatric CancersSkin Cancer
News
Clinical TopicsIntegrative CareGlobal BulletinAll NewsApproval Alert
Media
2 Minute DrillAround the PracticeBetween the LinesClinical ConsultExpert InterviewsFace OffMedical World NewsOncViewPodcastsReadout 360Year in Review
Conferences
Publications
All JournalsFor AuthorsTumor Board
Events
Frontline Forum
CME/CE
Resources
Contemporary ConceptsInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsored
Subscribe
eNewsletterPrint Subscription

  • About
  • Advertise
  • CureToday.com
  • OncLive.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
  • MJHLS Brand Logo

© 2022 MJH Life Sciences and Cancer Network. All rights reserved.

Spotlight
  • 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
  • CancerNetwork® Inaugural Face-Off
  • Contemporary Concepts in Hematologic Oncology
  • Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
  • Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
  • Real-World Evidence in NSCLC Guides Clinical Decisions
  • Register: Developments in GVHD Prevention and Treatment
  • Targeting NSCLC with Uncommon EGFR Mutations
ClinicalSee All >
  • Acute Myeloid Leukemia
  • Brain Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancer
  • Gynecologic Cancer
  • Hematology
  • Leukemia
  • Lung Cancer
  • Lymphoma
  • Pediatric Cancers
  • Skin Cancer
  • About
  • Advertise
  • CureToday.com
  • OncLive.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
  • MJHLS Brand Logo

© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.

Relapsed/Refractory Multiple Myeloma: Targeted Therapy and BCMA

Sagar Lonial, MD, FACP, explains the various ways to target and treat relapsed/refractory multiple myeloma, specifically focusing on BCMA and belantamab mafoditin as therapeutic agents.

EP. 1: Treatment Goals and Options for RRMM

May 3rd 2021

A multiple myeloma expert introduces and defines relapsed/refractory myeloma and discusses typical treatment strategies.

EP. 2: Considerations for Selecting Therapy in RRMM

May 3rd 2021

Sagar Lonial, MD, FACP, reviews targeted therapy options, and how they differ from other therapeutic approaches for relapsed/refractory myeloma.

EP. 3: BCMA as a Therapeutic Target for RRMM

May 3rd 2021

Dr Sagar Lonial, MD, FACP, comments on BCMA as a potential therapeutic target for multiple myeloma.

EP. 4: The DREAMM-2 Trial

May 3rd 2021

A leading myeloma expert reviews important data that led to the approval of belantamab mafodotin for heavily pretreated patients with relapsed/refractory multiple myeloma.

EP. 5: BCMA-Targeted Therapies for NDMM

May 3rd 2021

Sagar Lonial, MD, FACP, provides insight on the potential role of BCMA-targeted therapies for newly diagnosed patients with multiple myeloma.

EP. 6: Future Directions in MM Therapeutics

May 3rd 2021

Dr Sagar Lonial, MD, FACP, shares his thoughts on the future of targeted therapies for patients with multiple myeloma.